DashboardPortfoliosWatchlistCommunityDiscoverScreener
Loading...
  • Community
  • /
  • United States
  • /
  • Consumer Services
  • /
  • Allurion Technologies
Back to narrative

AnalystConsensusTarget updated the narrative for ALUR

ALUR logo

Low-dose GLP-1 Combo And FDA Approval Will Expand Obesity Care

ALUR logo
ALUR
A
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Published 20 Apr 2025
4 viewsusers have viewed this narrative update

Update shared on 24 Apr 2025

Next
20 Nov
US$1.17
AnalystConsensusTarget's Fair Value
US$7.00
83.3% undervalued intrinsic discount
1Y
-96.3%
7D
-33.1%
Loading
1Y
-96.3%
7D
-33.1%

Have other thoughts on Allurion Technologies?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Valuator
Company Info
Notes
AnalystConsensusTarget'sFair Value
US$10.63
89.0% undervalued intrinsic discount
Future estimation in
PastFuture-69m101m20212022202320242025202620272028Revenue US$100.8mEarnings US$11.7m
Revenue
Profit Margin
Future PE
Est. Revenue
$
Forecast revenue growth rate
0.00%
Historical revenue growth rate
N/A
Consumer Services revenue growth rate
1.14%
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
%
0
Decrease
Increase
Current discount rate
12.54%
Calculation
US$11.69m
Earnings '28
x
20.70x
PE Ratio '28
=
US$241.96m
Market Cap '28
US$241.96m
Market Cap '28
/
16.38m
No. shares '28
=
US$14.77
Share Price '28
US$14.77 Share Price '28
Discounted to 2025 @ 11.60% p.a.
=
US$10.62
Fair Value '25